Study: NCT01684878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (Chemotherapy)
Description: Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine (Chemotherapy)
Description: Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Chemotherapy)
Description: Participants administered paclitaxel at a dosage of 80 mg/m\^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Chemotherapy)
Description: Participants administered paclitaxel at a dosage of 80 mg/m\^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Chemotherapy)
Description: Participants administered paclitaxel at a dosage of 80 mg/m\^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel (Chemotherapy)
Description: Participants administered paclitaxel at a dosage of 80 mg/m\^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan (Chemotherapy)
Description: Participants administered topotecan at a dosage of 1.25 mg/m\^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan (Chemotherapy)
Description: Participants administered topotecan at a dosage of 1.25 mg/m\^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topotecan (Chemotherapy)
Description: Participants administered topotecan at a dosage of 1.25 mg/m\^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.